There are currently 44 active clinical trials seeking participants for Brain Metastases research studies. The states with the highest number of trials for Autism participants are Michigan, California, New York and North Carolina.
Assess Use of 18F-Fluciclovine for Patients With Large Brain Metastases Treated With Staged Stereotactic Radiosurgery
Recruiting
The spread of cancer to the brain is referred to as brain metastases. Brain metastases are a common complication of cancer. This study is being done to determine whether the use of a new imaging agent, 18F-fluciclovine, is able to detect which patients are responding to radiation therapy. In addition, this study will look at the changes of the treated brain metastases using this imaging agent over time.
Gender:
All
Ages:
18 years and above
Trial Updated:
12/26/2023
Locations: Miami Cancer Institute, Miami, Florida
Conditions: Brain Metastases, Adult, Brain Metastases, Brain Cancer
Developing a New MRI Technique to Understand Changes in Brain Tumors After Treatment
Recruiting
The purpose of this study is to develop and test a new magnetic resonance imaging (MRI) technique to see if it can be used to tell the difference between tumor growth from worsening of cancer and growth from the effects of treatment in participants who have brain tumors treated with radiation therapy called stereotactic radiosurgery (SRS).
Gender:
All
Ages:
18 years and above
Trial Updated:
12/18/2023
Locations: Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York, New York
Conditions: Brain Metastases, Brain Metastases, Adult, Metastatic Brain Tumor, Metastatic Brain Cancer
Phase II Study of Pembrolizumab in Combination With Lenvatinib in Patients With TNBC, NSCLC, and Other Tumor Types and Brain Metastases
Recruiting
This is a single-center, open-label, multi-cohort Phase II study evaluating the efficacy and safety of pembrolizumab in combination with lenvatinib in patients with solid tumors and brain metastases. The study will be comprised of 3 patient cohorts: triple negative breast cancer (TNBC), non-small cell lung cancer (NSCLC), and solid tumor types other than TNBC and NSCLC. Cohort 3 will be comprised of solid tumor types with established (e.g., renal cell carcinoma [RCC], endometrial cancer) or pre... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
11/28/2023
Locations: M D Anderson Cancer Center, Houston, Texas
Conditions: Brain Metastases, Tumor
Phase II Trial of the PARP Inhibitor Niraparib and PD-1 Inhibitor Dostarlimab in Patients With Advanced Cancers With Active Progressing Brain Metastases (STARLET)
Recruiting
To learn if the combination of niraparib and dostarlimab can help to control advanced cancer that has spread to the brain.
Gender:
All
Ages:
18 years and above
Trial Updated:
11/22/2023
Locations: M D Anderson Cancer Center, Houston, Texas
Conditions: Brain Metastases
Analyzing Preoperative Stereotactic Radiosurgery With Gamma Knife Icon for Brain Metastases
Recruiting
This is a single-arm, single-center pilot study in which 10 patients with one to four brain metastases diagnosed on brain magnetic resonance imaging (MRI) within the past 30 days will be evaluated for study eligibility and enrolled as appropriate.
Gender:
All
Ages:
18 years and above
Trial Updated:
11/22/2023
Locations: Froedtert Hospital & Medical College of Wisconsin, Milwaukee, Wisconsin
Conditions: Brain Metastases
Fluorine-18-AlphaVBeta6-Binding Peptide Positron Emission Tomography in Metastatic Non-Small Cell Lung Cancer
Recruiting
This study investigates fluorine-18-AlphaVBeta6-BP ([18F]-αvβ6-BP) as a Positron Emission (PET) imaging agent in Non-Small Cell Lung Cancer (NSCLC) patients with brain metastases. Investigators hypothesize that [18F]-αvβ6-BP PET/Computed Tomography (CT) is a sensitive tool for disease assessment in patients with metastatic NSCLC, including those with brain metastases.
Gender:
All
Ages:
18 years and above
Trial Updated:
11/16/2023
Locations: The University of California Davis Comprehensive Cancer Center, Sacramento, California
Conditions: Lung Cancer, Lung Cancer Metastatic, Brain Metastases, Non Small Cell Lung Cancer
A Study of Cabozantinib and Nivolumab With Radiation Therapy for People With Renal Cell Carcinoma That Has Spread to the Brain
Recruiting
The purpose of this study is to find out whether the combination of cabozantinib, nivolumab, and radiation therapy is a safe and effective treatment that causes few or mild side effects in people with renal cell cancer that has spread to the brain. The researches will also look at how the study treatment affects the quality of life of participants. They will measure the quality of life by having participants complete questionnaires.
Gender:
All
Ages:
18 years and above
Trial Updated:
11/10/2023
Locations: Memorial Sloan Kettering Basking Ridge (All Protocol Activities), Basking Ridge, New Jersey +6 locations
Conditions: Metastatic Renal Cell Carcinoma, Brain Metastases
A Phase II Study of Nivolumab With Ipilimumab and Cabozantinib in Patients With Untreated Renal Cell Carcinoma Brain Metastases
Recruiting
A Phase II Study of Nivolumab with Ipilimumab and Cabozantinib in Patients with Untreated Renal Cell Carcinoma Brain Metastases
Gender:
All
Ages:
18 years and above
Trial Updated:
10/26/2023
Locations: M D Anderson Cancer Center, Houston, Texas
Conditions: Brain Metastases, Renal Cell Carcinoma
Tucatinib, Trastuzumab, and Capecitabine With SRS for Brain Metastases From HER-2 Positive Breast Cancer
Recruiting
This research study will evaluate how well brain metastases associated with HER-2 positive breast cancer can be controlled using a type of radiation known as stereotactic radiosurgery (SRS) when combined with three therapeutic agents, tucatinib, capecitabine, and trastuzumab. The combined use of SRS with the three drugs is considered investigational.
Gender:
All
Ages:
18 years and above
Trial Updated:
09/26/2023
Locations: Miami Cancer Institute at Baptist Health, Inc., Miami, Florida
Conditions: Brain Metastases, HER2-positive Breast Cancer
Stereotactic Brain-directed Radiation With or Without Aguix Gadolinium-Based Nanoparticles in Brain Metastases
Recruiting
The purpose of this study is to determine whether AGuIX (Activation and Guidance of Irradiation by X-ray) gadolinium-based nanoparticles make radiation work more effectively in the treatment of patients with brain metastases that are more difficult to control with stereotactic radiation alone.
Gender:
All
Ages:
18 years and above
Trial Updated:
09/21/2023
Locations: Brigham and Women's Hospital, Boston, Massachusetts +1 locations
Conditions: Brain Cancer, Brain Metastases, Melanoma, Lung Cancer, Breast Cancer, HER2-positive Breast Cancer, Colorectal Cancer, Gastrointestinal Cancer, SRS, SRT, Whole Brain Radiation, Stereotactic Radiation, AGuIX, Nanoparticle, Cystic, Brain Tumor
Hippocampal Sparing Whole Brain Radiation Versus Stereotactic Radiation in Patients With 5-20 Brain Metastases: A Phase III, Randomized Trial
Recruiting
This research study is studying two different types of radiation as treatment for brain metastases (tumors in the brain that spread from a cancer that originated elsewhere in the body)
Gender:
All
Ages:
Between 18 years and 80 years
Trial Updated:
09/21/2023
Locations: Brigham and Women's Hospital, Boston, Massachusetts +1 locations
Conditions: Brain Metastases
Evaluation of the CONVIVO System
Recruiting
The primary objective of this study is to evaluate the diagnostic performance of the CONVIVO confocal endomicroscope in discriminating between normal and abnormal tissue in vivo during brain tumor surgery. The interpretation of intraoperative images obtained in situ will be tested against conventional histologic evaluation of targeted biopsies from imaged tissue. The study team hypothesize that there will be a high degree of correlation between images obtained with the CONVIVO system and convent... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
08/29/2023
Locations: Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire
Conditions: Glioblastoma, Glial Tumor, Brain Metastases, Meningioma, Schwannoma, Pituitary Tumor